Durable Long-Term Survival Observed for Patients with Germ Cell Tumors

Share this content:

(ChemotherapyAdvisor) – Patients with relapsed or refractory germ cell tumors achieve durable long-term survival after single or sequential high-dose chemotherapy; however, overall survival at five years with sequential therapy is superior due to fewer toxic deaths, a study published in the Journal of Clinical Oncology online January 30 has found.

Jörg Beyer, MD, of the Klinik für Hämatologie and Onkologie, Berlin, Germany, and colleagues reported on the long-term survival of 211 patients randomly assigned between November 1999 and November 2004 to either one cycle of cisplatin 100mg/m2, etoposide 375mg/m2, and ifosfamide 6g/m2 (VIP) plus three cycles of high-dose carboplatin 1,500mg/m2 and etoposide 1,500mg/m2 (arm A, n=108); or three cycles of VIP plus one cycle of high-dose carboplatin 2,200 mg/m2, etoposide 1,800mg/m2, and cyclophosphamide 6,400mg/m2 (arm B, n=103) followed by autologous stem-cell reinfusion.

Excess treatment-related mortality in arm B stopped the study prematurely. At six years after random assignment of the last patient, long-term progression-free survival (PFS) and overall survival (OS) were compared. As of December 2010, 94 of 211 patients (45%) were alive, 88 (94%) of whom were progression free; 9 (5%) were lost to follow-up. Five-year PFS was 47% in arm A and 45% in arm B (HR 1.16); and 5-year OS was 49% in arm A and 39% in arm B (HR 1.42; P=0.057).

“This analysis confirms that relapses or progressions after two years are rare events and supports the concept that PFS at two years can be used as a surrogate marker for long-term remission or cure in patients with relapsed or refractory germ cell tumors,” the investigators concluded.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs